Skip to main content
SpringerLink
Log in

Hémopathies malignes

  • Chapter
Précis d’hématologie et d’oncologie

  • 828 Accesses

Résumé

Déf.: Hémopathie maligne de la lignée lymphoïde avec transformation d’un précurseur lymphoblastique, arrêt de la différentiation et expansion clonale. Elle est caractérisée par la suppression de l’hématopoïèse normale, l’infiltration des organes extramédullaires et la libération de cellules leucémiques dans le sang périphérique.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Réf.

  1. Aplenc R, Lange B. Pharmacogenetic determinants of outcome in acute lymphoblastic leukemia. Br J Hematol 2004;125:421–434

    CAS  Google Scholar 

  2. Armstrong SA, Look AT. Molecular genetics of acute lymphoblastic leukemia. J Clin Oncol 2005;23:6306–6315

    PubMed  CAS  Google Scholar 

  3. Castor A, Nilsson L, Astrand-Grundstroem I et al. Distinct patterns of stem cell involvement in acute lymphoblastic leukemia. Nat Med 2005; 11:630–637

    PubMed  CAS  Google Scholar 

  4. Hallbook H, Hagglund H, Stockelberg D et al. Autologous and allogeneic stem cell transplantation in adult ALL. Bone Marrow Transpl 2005;35:1141–1148

    CAS  Google Scholar 

  5. Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Eng J Med 2006;354:166–178

    CAS  Google Scholar 

  6. Ravandi F. Role of cytokines in the treatment of acute leukemias. Leukemia 2006;20:563–571

    PubMed  CAS  Google Scholar 

  7. Rowe JM, Goldstone AH. How I treat acute lymphocytic leukemia in adults. Blood 2007;110:2268–2275

    PubMed  CAS  Google Scholar 

  8. Szczepanski T. Why and how to quantify minimal residual disease in acute lymphoblastic leukemia. Leukemia 2007;21:622–626

    PubMed  CAS  Google Scholar 

Réf.

  1. Bullinger L, Valk PJM. Gene-expression profiling in acute myeloid leukemia. J Clin Oncol 2005;23:6296–6305

    PubMed  CAS  Google Scholar 

  2. Craddock C, Tauro S, Moss P et al. Biology and management of relapsed acute myeloid leukemia. Br J Hematol 2005;129:18–34

    CAS  Google Scholar 

  3. Drobyski WR. The role of allogeneic transplantation in high-risk acute myelogenous leukemia. Leukemia 2004;18:1565–1568

    PubMed  CAS  Google Scholar 

  4. Estey H, Dönner H. Acute myeloid leukemia. Lancet 2006;368:1894–1907.

    PubMed  Google Scholar 

  5. Fey MF, ESMO Guidelines Task Force. Acute myeloblastic leukemia in adult patients: ESMO Clinical Recommendations for diagnosis, treatment and follow up. Ann Oncol 2007;18(suppl2):ii47–89

    PubMed  Google Scholar 

  6. Milligan DW, Grimwade D, Cullis JO et al. British Committee for Standards in Haematology. Guidelines on the management of acute myeloid leukemia in adults. Br J Haematol 2006;135:450–474

    PubMed  CAS  Google Scholar 

  7. Sekeres MA, Stone RM. The challenge of acute myeloid leukemia in older patients. Curr Opin Oncol 2002;14:24–30

    PubMed  Google Scholar 

  8. Tallmann MS, Gilliland DG, Rowe JM. Drug therapy for acute myeloid leukemia. Blood 2005;106:1154–1163

    Google Scholar 

  9. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002;100:2292–2302

    PubMed  CAS  Google Scholar 

Réf.

  1. Aul C, Giagounidis A, Germing U et al. A. Evaluating the prognosis of patients with myelodysplastic syndromes. Ann Hematol 2002; 81:485–497

    PubMed  CAS  Google Scholar 

  2. Bowen D, Culligan D, Jowitt S et al. Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes. Br J Hematol 2003;120:187–200

    Google Scholar 

  3. Corey SJ, Minden MD, Barber DL et al. MDS: the complexity of stem-cell diseases. Nat Rev Cancer 2007;7:118–129

    PubMed  CAS  Google Scholar 

  4. Golshayan AR, Jin T, Maciejewski J et al. Efficacy of growth factors compared to other therapies for low-risk MDS. Br J Haematol 2007,137:125–132

    PubMed  CAS  Google Scholar 

  5. Howe RB, Porwit-MacDonald A, Wanat R et al. The WHO classification of MDS does make a difference. Blood 2004;103:3265–3270

    PubMed  CAS  Google Scholar 

  6. Luger S, Sacks N. Bone marrow transplantation for myelodysplastic syndrome: who? when? and which? Bone Marrow Transpl 2002;30:199–206

    CAS  Google Scholar 

  7. Malcovati L, Germing U, Kuendgen A et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in MDS. J Clin Oncol 2007;25:3503–3510

    PubMed  Google Scholar 

  8. Olney HJ, LeBeau MM. Evaluation of recurring cytogenetic abnormalities in the treatment of MDS. Leukemia Res 2007;31:427–434

    CAS  Google Scholar 

  9. Valent P, Horny HP, Bennet JM et al. Definitions and standards in the diagnosis and treatment of MDS: Consensus statements and report from a working conference. Leukemia Res 2007;31:727–736

    Google Scholar 

Réf.

  1. Campell PJ, Green AR. The myeloproliferative disorders. N Engl J Med 2006;355:2452–2466

    Google Scholar 

  2. James C, Ugo V, LeCouedic JP et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythemia vera. Nature 2005;434:1144–1148

    PubMed  CAS  Google Scholar 

  3. Kaushansky K. On the molecular origins of the chronic myeloproliferative disorders: it all makes sense. Blood 2005;105:4187–4190

    PubMed  CAS  Google Scholar 

  4. Kralovics R, Passamonti F, Buser AS et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005;352:1779–1790

    PubMed  CAS  Google Scholar 

  5. Michiels JJ, De Raeve H, Hebeda K et al. WHO bone marrow features and European clinical, molecular and pathological (ECMP) criteria for the diagnosis of myeloproliferative disorders. Leukemia Res 2007;31:1031–1038

    CAS  Google Scholar 

  6. Spivak JL, Barosi G, Tognoni G et al. Chronic myeloproliferative disorders. Hematology (ASH Educ Program) 2003:200–224

    Google Scholar 

Réf.

  1. Baccarani M, Sglio G, Goldman J et al. Evolving concepts in the management of CML: recommendations from an expert panel on behalf of the European Leukemia Net. Blood 2006;108:1809–1820

    PubMed  CAS  Google Scholar 

  2. Calabretta B, Perrotti D. The biology of CML blast crisis. Blood 2004;103:4010–4022

    PubMed  CAS  Google Scholar 

  3. Cortes C, Kantarjian HM. New targeted approaches in chronic myeloid leukemia. J Clin Oncol 2005;23:6316–6324

    PubMed  CAS  Google Scholar 

  4. Goldman J. How I treat CML in the imatinib era. Blood 2007;110:2828–2837

    PubMed  CAS  Google Scholar 

  5. Hehlmann R, Hochhaus A, Baccarani M et al. Chronic myeloid leukemia. Lancet 2007;370:342–350

    PubMed  CAS  Google Scholar 

  6. Melo JV, Barnes DJ. CML as a model of a disease evolution in human cancer. Nat Rev Cancer 2007;7:441–453

    PubMed  CAS  Google Scholar 

  7. Schiffer CA. BCR-ABL tyrosine kinase inhibitors for CML. N Engl J Med 2007;357:258–265

    PubMed  CAS  Google Scholar 

  8. Simonsson B, ESMO Guidelines Working Group. CML: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 2007;18(suppl.2)ii61–62

    Google Scholar 

  9. Ren R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukemia. Nat Rev Cancer 2005;5:172–183

    PubMed  CAS  Google Scholar 

Réf.

  1. Elliott MA, Tefferi A. Thrombosis and hemorrhage in polycythemia vera and essential thrombocythemia. Br J Hematol 2004; 128:275–290

    Google Scholar 

  2. Finazzi G, Caruso V, Marchioli R et al. Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. Blood 2005;105:2664–2670

    PubMed  CAS  Google Scholar 

  3. James C, Ugo V, Le Couedic JP et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythemia vera. Nature 2005;434:1144–1148

    PubMed  CAS  Google Scholar 

  4. Landolfi R, Marchioli R, Kutti J et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 2004;350:114–124

    PubMed  CAS  Google Scholar 

  5. Levine L, Pardanani A, Tefferi A et al. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer 2007;7:673–683.

    PubMed  CAS  Google Scholar 

  6. McMullin MF, Bareford D, Campbell P et al. Guidelines for the diagnosis, investigation and management of polycythemia/erythrocytosis. Br J Hematol 2005;130:174–195

    Google Scholar 

  7. Schrader Al. Molecular basis of the diagnosis and treatment of polycythemia vera and essential thrombocythemia. Blood 2006;107:4214–4222.

    Google Scholar 

  8. Tefferi A, Thiele J, Orazi A et al. Proposals and rationale for revision of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 2007;110:1092–1097.

    PubMed  CAS  Google Scholar 

Réf.

  1. Campbell PJ, Green AR. Management of polycythemia vera and essential thrombocythemia. ASH Educational Program Book 2005:201–208

    Google Scholar 

  2. Chim CS, Kwong YL, Lie AK et al. Long-term outcome of 231 patients with essential thrombocythemia. Arch Intern Med 2005;165:2651–2658

    PubMed  Google Scholar 

  3. Finazzi G, Harrison CN. Essential thrombocythemia. Semin Hematol 2005;42:230–238

    PubMed  CAS  Google Scholar 

  4. Harrison CN. Essential thrombocythaemia: challenges and evidence-based management. Br J Haematol 2005;130:153–165

    PubMed  Google Scholar 

  5. Harrison CN, Campbell PJ, Buck G et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 2005;353:33–45

    PubMed  CAS  Google Scholar 

  6. Schafer AI. Thrombocytosis. N Engl J Med 2004;350:1211–1219

    PubMed  CAS  Google Scholar 

  7. Steurer M, Gastl G, Jedrzejczak WW et al. Anagrelide for thrombocytosis in myeloproliferative disorders. Cancer 2004;101:2239–2246

    PubMed  CAS  Google Scholar 

  8. Tefferi A, Thiele J, Orazi A et al. Proposals and rationale for revision of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 2007;110:1092–1097

    PubMed  CAS  Google Scholar 

Réf.

  1. Arana-Yi C, Quintas-Cardama A, Giles F et al. Advances in the therapy of chronic idiopathic myelofibrsis. Oncologist 2006;11:929–943

    PubMed  CAS  Google Scholar 

  2. Barosi G, Bergamaschi G, Marchetti M et al. JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. Blood 2007;110:4030–4036

    PubMed  CAS  Google Scholar 

  3. Cervantes F. Modern management of myelofibrosis. Br J Haematol 2005;128:585–592

    Google Scholar 

  4. Ciurea SO, Merchant D, Mahmud N et al. Pivotal contributions of megakaryocytes to the biology of idiopathic myelofibrosis. Blood 2007;110:986–993

    PubMed  CAS  Google Scholar 

  5. Henessy BT, Thomas DA, Giles FJ et al. New approaches in the treatment of myelofibrosis. Cancer 2005;103:32–43

    Google Scholar 

  6. Papageorgiou SG, Castleton A, Bloor A et al. Allogeneic stem cell transplantation as treatment for myelofibrosis. Bone Marrow Transplant 2006;38:721–727

    PubMed  CAS  Google Scholar 

  7. Tefferi A, Thiele J, Orazi A et al. Proposals and rationale for revision of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 2007;110:1092–1097

    PubMed  CAS  Google Scholar 

Réf.

  1. Bonadonna G, Viviani S, Bonafante V et al. Survival in Hodgkin’s lymphoma. Eur J Cancer 2005;41:998–1006

    PubMed  Google Scholar 

  2. Connors JM. State-of-art therapeutics: Hodgkin’s lymphoma. J Clin Oncol 2005;23:6400–6408

    PubMed  CAS  Google Scholar 

  3. Diehl V, Fuchs M. Early, intermediate and advanced Hodgkin’s lymphoma: modern treatment strategies. Ann Oncol 2007;18(Suppl. 9):ix71–79

    PubMed  Google Scholar 

  4. Ferme C, Eghbali H, Meerwaldt JH et al. Chemotherapy plus involved field radiation in early stage Hodgkin’s disease. N Engl J Med 2007;357:1916–1927

    PubMed  CAS  Google Scholar 

  5. Jost L, ESMO Guidelines Working Group. Hodgkin’s disease: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 2007;18(Suppl. 2):ii53–54

    PubMed  Google Scholar 

  6. Lavoien JC, Connors JM, Phillips GL et al. High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin’s lymphoma. Blood 2005; 106:1473–1478

    Google Scholar 

  7. Peggs KS, Hunter A, Chopra R et al. Clinical evidence of graft-versus-Hodgkin’s lymphoma effect after reduced-intensity allogenic transplantation. Lancet 2005;365:1934–1941

    PubMed  Google Scholar 

  8. Re D, Küppers R, Diehl V. Molecular pathogenesis of Hodgkin’s lymphoma. J Clin Oncol 2005;23:6379–6386

    PubMed  CAS  Google Scholar 

  9. Yung L, Linch D. Hodgkin’s lymphoma. Lancet 2003;361:943–951

    PubMed  Google Scholar 

Réf.

  1. Armitage JO. Staging non-Hodgkin lymphoma. CA Cancer J Clin 2005;55:368–376

    PubMed  Google Scholar 

  2. Cheson BD, Pflster B, Juweid ME et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579–586

    PubMed  Google Scholar 

  3. Evans LS, Hancock BW. Non-Hodgkin lymphoma. Lancet 2003;362:139–146

    PubMed  CAS  Google Scholar 

  4. Fisher SG, Fisher RI. The epidemiology of non-Hodgkin’s lymphoma. Oncogene 2004;23:6524–6534

    PubMed  CAS  Google Scholar 

  5. Jaffe ES, Harris NL, Stein H et al. (eds) Pathology and Genetics of Tumors of the Hematopoietic and Lymphoid Tissues. WHO classification of tumors, IARC Press, Lyon, 2001

    Google Scholar 

  6. Kwee TC, Kwee RM, Nievelstein RAJ. Imaging in staging of malignant lymphoma. Blood 2008;111:504–516

    PubMed  CAS  Google Scholar 

  7. Pals ST, De Gorter DJJ, Spaargaren M. Lymphoma dissemination: the other face of lymphocyte homing. Blood 2007;110:3102–3111.

    PubMed  CAS  Google Scholar 

  8. Rizvi MA, Evens, AM, Tallman MS et al. T-cell non-Hodgkin lymphoma. Blood 2006; 107:1255–1264

    PubMed  CAS  Google Scholar 

Réf.

  1. Abramson JS, Shipp MA. Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach. Blood 2005; 106:1164–1174

    PubMed  CAS  Google Scholar 

  2. Armitage JO. How I treat patients with diffuse large B-cell lymphoma. Blood 2007;110:29–36

    PubMed  CAS  Google Scholar 

  3. Coiffier B, Lepage E, Brière J et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235–242

    PubMed  CAS  Google Scholar 

  4. ESMO Guidelines Task Force. Relapsed large B-cell non-Hodgkin’ lymphoma. ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 2007;18(Suppl.2):ii55–56

    Google Scholar 

  5. ESMO Guidelines Task Force. Newly diagnosed large B-cell non-Hodgkin’s lymphoma. ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 2007;18(Suppl.2):ii57–58

    Google Scholar 

  6. Ferry JA. Burkitt’s lymphoma. Oncologist 2006;11:375–383

    PubMed  Google Scholar 

  7. Milpied N, Deconinck E, Gaillard F et al. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med 2004;350:1287–1295

    PubMed  CAS  Google Scholar 

  8. Pfreundschuh M, Trümper L, Kloess M et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood 2004;104:626–633

    PubMed  CAS  Google Scholar 

  9. Seropian S, Bahceci E, Cooper DL. Allogeneic peripheral blood stem cell transplantation for high-risk non-Hodgkin’s lymphoma. Bone Marrow Transpl 2003;32:763–769

    CAS  Google Scholar 

Réf.

  1. Abbott BL. Chronic lymphocytic leukemia. Oncologist 2006;11:21–30

    PubMed  CAS  Google Scholar 

  2. Auer RL, Gribben J, Cotter FE. Emerging therapy for chronic lymphocytic leukaemia. Brit J Haematol 2007;139:635–644.

    CAS  Google Scholar 

  3. Catovsky D, Richards S, Matutes E et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia. Lancet 2007;370:230–239

    PubMed  CAS  Google Scholar 

  4. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med 2005;352:804–815

    PubMed  CAS  Google Scholar 

  5. ESMO Guidelines Working Group. Chronic lymphocytic leukemia: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 2007;18(Suppl. 2):ii49–50

    Google Scholar 

  6. Montserrat E, Moreno C, Esteve J et al. How I treat refractory CLL. Blood 2006; 107:1276–1283

    PubMed  CAS  Google Scholar 

  7. Linet MS, Schubauer-Berigan MK, Weisenburger DD et al. Chronic lymphocytic leukaemia: an overview of aetiology in light of recent developments in classification and pathogenesis. Brit J Haematol 2007;139:672–686.

    Google Scholar 

  8. Wierda WG, Kipps TJ, Keating MJ. Novel immune-based treatment strategies for chronic lymphocytic leukemia. J Clin Oncol 2005;23:6325–6332

    PubMed  CAS  Google Scholar 

Réf.

  1. Absi H, Hsi E, Kalaycio M. Prolymphocytic leukemia. Curr Treat Options Oncol 2005;6:197–208

    PubMed  Google Scholar 

  2. Cao TM, Coutre SE. T-cell prolymphocytic leukemia: update and focus on alemtuzumab. Hematology 2003;8:1–6

    PubMed  CAS  Google Scholar 

  3. Castagna L, Nozza A, Bertuzzi A et al. Allogeneic peripheral blood stem cell transplantation with reduced intensity conditioning in primary refractory prolymphocytic leukemia. Bone Marrow Transplant 2001;28:1155–1166

    PubMed  CAS  Google Scholar 

  4. Dearden CE, Matutes E, Cazin B et al. High remission rate in T-cell prolymphocytic leukemia with CAM-PATH-1H. Blood 2001;98:1721–1726

    PubMed  CAS  Google Scholar 

  5. McCune SL, Gockerman JP, Moore JO et al. Alemtuzumab in relapsed or refractory chronic lymphocytic leukemia and prolymphocytic leukemia. Leuk Lymphoma 2002;43:1007–1011

    PubMed  CAS  Google Scholar 

  6. Montillo M, Tedeschi A, O’Brien S et al. Phase II study of cladribine and cyclophosphamide in patients with chronic lymphocytic leukemia and prolymphocytic leukemia. Cancer 2003;97:114–120

    PubMed  CAS  Google Scholar 

  7. Shvidel L, Shtalrid M, Bassous L et al. B-cell prolymphocytic leukemia: a survey of 35 patients emphasizing heterogeneity, prognostic factors and evidence for a group with an indolent course. Leuk Lymphoma 1999;33:169–179

    PubMed  CAS  Google Scholar 

  8. Valbuena JR, Herling M, Admirand JH et al. T-cell prolymphocytic leukemia involving extramedullary sites. Am J Clin Pathol 2005;123:456–464

    PubMed  Google Scholar 

Réf.

  1. Else M, Ruchlemer R, Osuji N et al. Long remissions in hairy cell leukemia with purine analogues. Cancer 2005;104:2442–2448

    PubMed  CAS  Google Scholar 

  2. Falini B, Tiacci E, Liso A et al. Simple diagnostic assay for hairy cell leukaemia by immunocytochemical detection of annexinA1 (ANXA1). Lancet 2004;363:1869–1871

    PubMed  CAS  Google Scholar 

  3. Goodman GR, Bethel KJ, Saven A. Hairy cell leukemia: an update. Curr Opin Hematol 2003;10:258–266

    PubMed  Google Scholar 

  4. Jehn U, Bartl R, Dietzfelbinger H et al. An update: 12-year follow-up of patients with hairy cell leukemia following treatment with 2-chlorodeoxyadenosine. Leukemia 2004;18:1476–1481

    PubMed  CAS  Google Scholar 

  5. Tiacci E, Liso A, Piris M et al. Evolving concepts in the pathogenensis of hairy-cell leukemia. Nat Rev Cancer 2006; 6:437–448

    PubMed  CAS  Google Scholar 

  6. Wanko SO, De Castro C. Hairy cell leukemia. Oncologist 2006;11:780–789

    PubMed  Google Scholar 

Réf.

  1. Advani R, Rosenberg SA, Horning SJ. Stage I and II follicular non-Hodgkin’s lymphoma: long-term followup of no initial therapy. J Clin Oncol 2005;22:1454–1459

    Google Scholar 

  2. Bende RJ, Smit LA, Van Noessel CJM. Molecular pathways in follicular lymphoma. Leukemia 2007;21:18–29.

    PubMed  CAS  Google Scholar 

  3. Brown J, Feng Y, Gribben JG. Long-term survival after autologous bone marrow transplantation for follicular lymphoma in first remission. Biol Blood Marrow Transpl 2007;12:1057–1065.

    Google Scholar 

  4. ESMO Guidelines Working Group. Newly diagnosed follicular lymphoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008;18(Suppl.2):ii63–64

    Google Scholar 

  5. Hiddemann W, Buske C, Dreyling M et al. Current management of follicular lymphomas. Br J Haematol 2006;136:191–202

    PubMed  Google Scholar 

  6. Kaminski MS, Tuck M, Estes J et al. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 2005;352:441–449

    PubMed  CAS  Google Scholar 

  7. Solal-Celigny P, Roy P, Colombat P et al. Follicular Lymphoma International Prognostic Index. Blood 2004;104:1258–1265

    PubMed  CAS  Google Scholar 

  8. Staudt LM. A closer look at follicular lymphoma. N Engl J Med 2007;356;741–742.

    PubMed  CAS  Google Scholar 

Réf.

  1. Bertoni F, Zucca E, Cavalli F. Mantle cell lymphoma. Curr Opin Hematol 2004;11:411–418

    PubMed  CAS  Google Scholar 

  2. Fernàndez V, Hartmann E, Ott G et al. Pathogenesis of mantle cell lymphoma: all oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways. J Clin Oncol 2005;23:6364–6369

    PubMed  Google Scholar 

  3. Hagemeister FB. Mantle cell lymphoma: non-myeloablative vs. dose-intensive therapy. Leuk Lymphoma 2003;44(suppl 3):S69–75

    PubMed  Google Scholar 

  4. Kiss TL, Mollee P, Lazarus HM et al. Stem cell transplantation for mantle cell lymphoma: if, when and how? Bone Marrow Transplant 2005;36:655–661

    PubMed  CAS  Google Scholar 

  5. Lenz G, Dreyling M, Hiddemann W. Mantle cell lymphoma: established therapeutic options and future directions. Ann Hematol 2004;83:71–77

    PubMed  CAS  Google Scholar 

  6. Leonard JP, Schattner EJ, Coleman M. Biology and management of mantle cell lymphoma. Curr Opin Oncol 2001;13:342–347

    PubMed  CAS  Google Scholar 

  7. Witzig TE. Current treatment approaches for mantle cell lymphoma. J Clin Oncol 2005;23:6409–6414

    PubMed  CAS  Google Scholar 

  8. Zelenetz AD. Mantle cell lymphoma. Ann Oncol 2006;17(suppl 4):iv12–14

    PubMed  Google Scholar 

Réf.

  1. ESMO Guidelines Working Group. Primary cutaneous lymphomas: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 2007;18(Suppl.2):ii61–62

    Google Scholar 

  2. Foss F. Mycosis fungoides and the Sézary syndrome. Curr Opin Oncol 2004;16:421–428

    PubMed  Google Scholar 

  3. Girardi M, Heald PW, Wilson LD. The pathogenesis of mycosis fungoides. N Engl J Med 2004;350:1978–1988

    PubMed  CAS  Google Scholar 

  4. Hwang ST, Janik JE, Jaffe ES et al. Mycosis fungoides and Sézary syndrome. Lancet 2008;371:945–957.

    PubMed  CAS  Google Scholar 

  5. Olsen E, Vonderheid E, Pimpinelli N et al. Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the ISCL and the cutaneous lymphoma task force of the EORTC. Blood 2007;110:1713–1722

    PubMed  CAS  Google Scholar 

  6. Querfeld C, Rosen ST, Guitart J et al. The spectrum of cutaneous T-cell lymphomas: new insights into biology and therapy. Curr Opin Hematol 2005;12:273–278

    PubMed  Google Scholar 

  7. Smith BD, Smith GL, Cooper DL et al. The cutaneous B-cell lymphoma prognostic index. J Clin Oncol 2005;23:3390–3395

    PubMed  Google Scholar 

  8. Trautinger F, Knobler R, Willemze R et al. EORTC consensus recommendations for the treatment of mycosis fungoides / Sézary syndrome. Eur J Cancer 2006;42:1014–1030

    PubMed  Google Scholar 

Réf.

  1. Abrey LE, Batchelor TT, Ferreri AJ et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol 2005;23:5034–5043

    PubMed  Google Scholar 

  2. Batchelor T, Loeffler JS. Primary CNS lymphoma. J Clin Oncol 2006;24:1281–1288

    PubMed  CAS  Google Scholar 

  3. Bessell EM, Hoang-Xuan K, Ferreri AJM et al. Primary central nervous system lymphoma — Biological aspects and controversies in management. Eur J Cancer 2007;43:1141–1152.

    PubMed  Google Scholar 

  4. DeAngelis LM, Hormigo A. Treatment of primary central nervous system lymphoma. Semin Oncol 2004;31:684–692

    PubMed  Google Scholar 

  5. Grimm SA, Pulido JS, Jahnke K et al. Primary intraocular lymphoma: an IPCNSLCG Report. Ann Oncol 2007;18:1851–1855.

    PubMed  CAS  Google Scholar 

  6. Nguyen PL, Chakravarti A, Finkelstein DM et al. Results of whole-brain radiation as salvage of methotrexate failure for immunocompetent patients with primary CNS lymphoma. J Clin Oncol 2005;23:1507–1513

    PubMed  Google Scholar 

  7. Omuro AM, DeAngelis LM, Yahalom J et al. Chemoradiotherapy for primary CNS lymphoma: an intent-to-treat analysis with complete follow-up. Neurology 2005;64:69–74

    PubMed  CAS  Google Scholar 

  8. Poortmans PMP, Kluin-Nelemans HC, Haaxma-Reiche H et al. High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma. J Clin Oncol 2003;21:4483–4488

    PubMed  CAS  Google Scholar 

  9. Illerhaus G, Marks R, Ihorst G et al. High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma. J Clin Oncol 2006;24:3865–3870

    PubMed  CAS  Google Scholar 

Réf.

  1. Bertoni F, Zucca E. State-of-the-art therapeutics: marginal-zone lymphoma. J Clin Oncol 2005;23:6415–6420

    PubMed  CAS  Google Scholar 

  2. Cohen SM, Petryk M, Varma M et al. Non-Hodgkin’s Lymhoma of Mucosa-Associated Lymphoid Tissue. Oncolist 2006;11:1100–1117

    CAS  Google Scholar 

  3. ESMO Guidelines Working Group. Gastric marginal zone lymphoma of mucosa-associated lymphoid tissue type: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 2007;18(Suppl.2):ii59–60

    Google Scholar 

  4. Farinha P, Gascoyne R. Molecular pathogenesis of mucosa-associated lymphoid tissue lymphoma. J Clin Oncologist 2005;26:6370–6378

    Google Scholar 

  5. Ferrucci PF, Zucca E. Primary gastric lymphoma pathogenesis and treatment: what has changes over the past 10 years? Br J Haematol 2006;136:521–538

    PubMed  Google Scholar 

  6. Isaacson PG, Du MQ. MALT lymphoma: from morphology to molecules. Nat Rev Cancer 2004;4:644–653

    PubMed  CAS  Google Scholar 

  7. Schmidt WP, Schmitz N, Sonnen R. Conservative management of gastric lymphoma: the treatment option of choice. Leuk Lymphoma 2004;45:1847–1852

    PubMed  Google Scholar 

Réf.

  1. Bensinger W. Stem-cell transplantation for multiple myeloma in the era of novel drugs. J Clin Oncol 2008;26:480–492

    PubMed  CAS  Google Scholar 

  2. Bladé J. Monoclonal Gammopathy of undetermined significance. N Engl J Med 2006;355:2765–2770

    PubMed  Google Scholar 

  3. Dimopoulos M, Spencer A, Attal M et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007;357:2123–2132

    PubMed  CAS  Google Scholar 

  4. ESMO Guidelines Working Group. Multiple myeloma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 2007;18(Suppl. 2):ii44–46

    Google Scholar 

  5. Gonzalez D, vander Burg M, García-Sanz M et al. Immunoglobulin gene rearrangements and the pathogenesis of multiple myeloma. Blood 2007;110:3112–3121

    PubMed  CAS  Google Scholar 

  6. Katzel JA, Hari P, Vesole DH. Multiple Myeloma: Charging Toward a Bright Future. CA Cancer J Clin 2007;57:301–318

    PubMed  Google Scholar 

  7. Kyle RA, Rajkumar SV. Multiple myeloma. Blod 2008;111:2962–2972

    CAS  Google Scholar 

  8. Kumar SK, Rajkumar SV, Dispenzieri A et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008;111:2516–2520

    PubMed  CAS  Google Scholar 

  9. Wechalekar AD, Hawkins PN, Gillmore JD. Perspectives in treatment of AL amyloidosis. Br J Haematol 2008;140:365–377

    PubMed  CAS  Google Scholar 

Réf.

  1. Chen CI. Treatment for Waldenström’s macroglobulinemia. Ann Oncol 2004;15:550–558

    PubMed  CAS  Google Scholar 

  2. Dimopoulos MA, Kyle RA, Anagnostopoulos A et al. Diagnosis and management of Waldenström’s macroglobulinemia. J Clin Oncol 2005;23:1564–1577

    PubMed  Google Scholar 

  3. Fonseca R, Hayman S. Waldenström macroglobulinaemia. Br J Haematol 2007;138:700–720

    PubMed  CAS  Google Scholar 

  4. Johnson SA, Birchall J, Luckie C et al. Guidelines on the management of Waldenström macroglobulinemia. Br J Haematol 2006;132:683–697

    PubMed  CAS  Google Scholar 

  5. Kyle RA, Treon SP, Alexanian R et al. Prognostic markers and criteria to initiate therapy in Waldenström’s macroglobulinemia. Semin Oncol 2003;30:116–120

    PubMed  Google Scholar 

  6. Treon SP, Gertz MA, Dimopoulos M et al. Update on treatment recommendations from the Third International Workshop on Waldenström’s macroglobulinemia. Blood 2006; 207:3442–3446

    Google Scholar 

Réf.

  1. Aricò M. Langerhans cell histiocytosis in adults: more questions than answers? Eur J Cancer 2004;40:1467–1473

    PubMed  Google Scholar 

  2. Gadner H, Grois N, Pötschger U et al. Improved outcome in multisystem Langerhans cell histiocytosis is associated with therapy intensification. Blood 2008;111:2556–2562

    PubMed  CAS  Google Scholar 

  3. Geissmann F, Lepelletier Y, Fraitag S et al. Differentiation of Langerhans cells in Langerhans cell histiocytosis. Blood 2001;97:1241–1248

    PubMed  CAS  Google Scholar 

  4. Götz G, Fichter J. Langerhans cell histiocytosis in 58 adults. Eur J Med Res 2004;9:510–514

    PubMed  Google Scholar 

  5. Steiner M, Matthes-Martin S, Attarbaschi A et al. Improved outcome of treatment-resistant high-risk Langerhans cell histiocytosis after allogeneic stem cell transplantation with reduced-intensity conditioning. Bone Marrow Transplant 2005;36:215–225

    PubMed  CAS  Google Scholar 

  6. Stockschlaeder M, Sucker C. Adult Langerhans cell histiocytosis. Eur J Haematol 2006;76:363–368

    PubMed  Google Scholar 

  7. Vassallo R, Ryu JH, Colby TV et al. Pulmonary Langerhans cell histiocytosis. N Engl J Med 2000;342:1969–1978

    PubMed  CAS  Google Scholar 

Réf.

  1. Akin C, Metcalfe DD. Systemic mastocytosis. Annu Rev Med 2004;55:419–432

    PubMed  CAS  Google Scholar 

  2. Kirshenbaum AS, Goff JP, Semere T et al. Demonstration that human mast cells arise from a progenitor cell population that is CD34+,c-kit+, and expresses aminopeptidase N (CD13). Blood 1999;94:2333–2342

    PubMed  CAS  Google Scholar 

  3. Ma Y, Zeng S, Metcalfe DD et al. The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors. Blood 1002;99:1741 4

    Google Scholar 

  4. Metcalfe DD, Akin C. Mastocytosis: molecular mechanisms and clinical disease heterogeneity. Leuk Res 2001;25:577–582

    PubMed  CAS  Google Scholar 

  5. Pardanani A, Ketterling RP, Brockman SR et al. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood 2003;102:3093–3096

    PubMed  CAS  Google Scholar 

  6. Tefferi A, Li CY, Butterfield JH et al. Treatment of systemic mast cell disease with cladribine. N Engl J Med 2001;344:307–309

    PubMed  CAS  Google Scholar 

  7. Valent P, Akin C, Sperr WR et al. Mastocytosis: pathology, genetics, and current options for therapy. Leuk Lymphoma 2005;46:35–48

    PubMed  CAS  Google Scholar 

  8. Yavuz AS, Lipsky PE, Yavuz S et al. Evidence for the involvement of a hematopoietic progenitor cell in systemic mastocytosis from single-cell analysis of mutations in the c-kit gene. Blood 2002;100:661–665

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. R. Wäsch
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. W. Digel
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Lübbert
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. K. Heining-Mikesch
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C. F. Waller
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. W. Lange
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. J. Heinz
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. J. Finke
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. J. Burger
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. G. Illerhaus
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. R. Marks
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. A. Spyridonidis
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. C. I. Müller
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. M. Engelhardt
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. M. Stockschläder
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer-Verlag France, Paris

About this chapter

Cite this chapter

Wäsch, R. et al. (2011). Hémopathies malignes. In: Précis d’hématologie et d’oncologie. Springer, Paris. https://doi.org/10.1007/978-2-287-99342-8_7

Download citation

  • DOI: https://doi.org/10.1007/978-2-287-99342-8_7

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-287-99341-1

  • Online ISBN: 978-2-287-99342-8

Publish with us

Policies and ethics

Search

Navigation